Highest-materiality recent filing
ResMed Q3 revenue $1.43B (+11%); GAAP EPS $2.74, dividend $0.60
Revenue $1,431.4M (+11% reported, +8% constant currency).
ResMed CFO Brett Sandercock retires; Aaron Bloomer appointed successor
Brett Sandercock retires as CFO effective May 4, 2026; remains special advisor to CEO through Dec 2027.
ResMed Q2 FY2026: Revenue $1.42B (+11% YoY), non-GAAP EPS $2.81, dividend $0.60
Revenue $1,422.8M, up 11% YoY (9% constant currency); gross margin expanded 320 bps to 61.8%.
Director Sulpizio not re-elected; board shrinks to 11; stockholders approve equity plan amendments
Richard Sulpizio did not seek re-election at Nov 19 annual meeting; board reduced from 12 to 11 directors.
ResMed Q1 FY2026 revenue +9% to $1.34B; non-GAAP EPS $2.55 (+16%); dividend $0.60
Revenue $1,335.6M (+9% YoY, +8% constant currency); diluted EPS $2.37, non-GAAP EPS $2.55 (+16%).
ResMed elects AbbVie's Nicole Mowad-Nassar to board; director Sulpizio to retire in Nov 2025
Nicole Mowad-Nassar elected to ResMed board effective Aug 15, 2025; she is SVP at AbbVie and President of Specialty & U.S. Therapeutics Operations.
ResMed CCO of residential care software business resigns effective Aug 1, 2025
Bobby Ghoshal, chief commercial officer of ResMed's RCS business, resigns effective August 1, 2025.
ResMed Q4 revenue up 10% to $1.35B, EPS $2.58; dividend raised 13% to $0.60
Q4 revenue $1.35B (+10% YoY, +9% CC); GAAP EPS $2.58 (+30%), non-GAAP EPS $2.55 (+23%).
ResMed Q3 FY2025: revenue $1.29B (+8%), GAAP EPS $2.48 (+22%), non-GAAP EPS $2.37 (+11%)
Revenue of $1.29B (+8% YoY; +9% constant currency); GAAP diluted EPS $2.48 vs $2.04 (+22%).
ResMed reports Q2 FY2025 revenue up 10% to $1.28B; non-GAAP EPS $2.43, up 29%
Revenue $1.28B (+10% YoY); gross margin 58.6% (+300 bps) on manufacturing efficiencies.
All 11 director nominees elected with strong support; vote tallies ranged from ~88M to ~109M in favor.
ResMed Q1 FY2025 revenue $1.22B (+11% YoY); EPS $2.11; non-GAAP EPS $2.20; dividend $0.53
Revenue $1,224.5M, up 11% YoY (11% constant currency), driven by sleep device and mask demand.
ResMed appoints Christopher DelOrefice to board of directors, effective August 15, 2024
DelOrefice is EVP and CFO of Becton Dickinson, brings 30+ years of audit, finance and strategic expertise.
ResMed Q4 revenue $1.22B (+9% YoY); EPS $1.98; dividend up 10% to $0.53
Q4 FY2024 revenue $1,223.2M (+9% YoY, +10% constant currency); gross margin 58.5% (+350 bps).
ResMed Q3 FY2024 revenue $1.20B, +7% YoY; GAAP EPS $2.04, non-GAAP $2.13
Revenue $1.197B up 7% YoY (7% constant currency); mask/accessories double-digit growth.
On April 30, 2026, the Company also announced it appointed Aaron Bloomer, age 40, as Chief Financial Officer, effective May 4, 2026.
On April 30, 2026, ResMed Inc. (the “Company”) announced that Brett Sandercock, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, will retire from his role as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer.
On August 15, 2024, ResMed Inc. appointed Christopher DelOrefice to serve on its board of directors, with a term expiring at ResMed’s 2024 annual meeting of stockholders on November 21, 2024
Max materiality 0.85 · Median 0.75 · Most common event earnings